MX348758B - Derivados de sanglifehrina y metodos para su produccion. - Google Patents
Derivados de sanglifehrina y metodos para su produccion.Info
- Publication number
- MX348758B MX348758B MX2013007055A MX2013007055A MX348758B MX 348758 B MX348758 B MX 348758B MX 2013007055 A MX2013007055 A MX 2013007055A MX 2013007055 A MX2013007055 A MX 2013007055A MX 348758 B MX348758 B MX 348758B
- Authority
- MX
- Mexico
- Prior art keywords
- production
- methods
- sanglifehrin
- derivatives
- sanglifehrin derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula (I) y (II) (Ver Formulas) y su uso en terapia, en particular para el tratamiento de la infección viral.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1021522.6A GB201021522D0 (en) | 2010-12-20 | 2010-12-20 | Novel compounds and methods for their production |
GBGB1113626.4A GB201113626D0 (en) | 2011-08-08 | 2011-08-08 | Novel compounds and methods for their production |
PCT/GB2011/052524 WO2012085553A1 (en) | 2010-12-20 | 2011-12-20 | Sanglifehrin derivatives and methods for their production |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013007055A MX2013007055A (es) | 2013-11-01 |
MX348758B true MX348758B (es) | 2017-06-28 |
Family
ID=45478358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013007055A MX348758B (es) | 2010-12-20 | 2011-12-20 | Derivados de sanglifehrina y metodos para su produccion. |
Country Status (11)
Country | Link |
---|---|
US (1) | US9271977B2 (es) |
EP (2) | EP3427737A1 (es) |
JP (2) | JP6086869B2 (es) |
KR (2) | KR101935213B1 (es) |
CN (2) | CN107090476B (es) |
BR (1) | BR112013015501A2 (es) |
CA (2) | CA2822347C (es) |
EA (1) | EA022408B1 (es) |
ES (1) | ES2703433T3 (es) |
MX (1) | MX348758B (es) |
WO (1) | WO2012085553A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3063B1 (ar) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
CN104877006A (zh) * | 2015-06-02 | 2015-09-02 | 宁夏泰益欣生物科技有限公司 | 一种利用萨菲菌素发酵液制备萨菲菌素粗品的方法 |
CN105695541B (zh) * | 2016-03-10 | 2019-03-15 | 苏州华赛生物工程技术有限公司 | 一种抗生素nvp018中间体的分离纯化方法 |
BR112019009903A2 (pt) | 2016-11-18 | 2019-08-13 | Neurovive Pharmaceutical Ab | análogo de sangliferina, combinação, composição farmacêutica, e, método para tratamento de um sujeito sofrendo de câncer ou de malignidade de célula-b |
WO2021142115A1 (en) * | 2020-01-09 | 2021-07-15 | President And Fellows Of Harvard College | Sanglifehrin analogs and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
AR006514A1 (es) * | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
WO2006138507A1 (en) * | 2005-06-17 | 2006-12-28 | Novartis Ag | Use of sanglifehrin in hcv |
JP5801534B2 (ja) | 2007-01-04 | 2015-10-28 | デビオファーム インターナショナル ソシエテ アノニム | ウールリッヒ型先天筋ジストロフィーの処置のための、非免疫抑制性シクロスポリン |
ES2556211T3 (es) | 2008-09-24 | 2016-01-14 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Agrupación de genes novedosa |
WO2011098805A1 (en) * | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
-
2011
- 2011-12-20 ES ES11808295T patent/ES2703433T3/es active Active
- 2011-12-20 EP EP18188805.8A patent/EP3427737A1/en not_active Withdrawn
- 2011-12-20 KR KR1020187006060A patent/KR101935213B1/ko active IP Right Grant
- 2011-12-20 CN CN201710086249.2A patent/CN107090476B/zh active Active
- 2011-12-20 CA CA2822347A patent/CA2822347C/en active Active
- 2011-12-20 EA EA201390925A patent/EA022408B1/ru not_active IP Right Cessation
- 2011-12-20 EP EP11808295.7A patent/EP2654753B1/en active Active
- 2011-12-20 US US13/995,666 patent/US9271977B2/en active Active
- 2011-12-20 CA CA3028414A patent/CA3028414C/en active Active
- 2011-12-20 JP JP2013545497A patent/JP6086869B2/ja active Active
- 2011-12-20 BR BR112013015501A patent/BR112013015501A2/pt not_active Application Discontinuation
- 2011-12-20 KR KR1020137018964A patent/KR101900974B1/ko active IP Right Grant
- 2011-12-20 MX MX2013007055A patent/MX348758B/es active IP Right Grant
- 2011-12-20 WO PCT/GB2011/052524 patent/WO2012085553A1/en active Application Filing
- 2011-12-20 CN CN201180068004.8A patent/CN103619336B/zh active Active
-
2016
- 2016-11-21 JP JP2016225660A patent/JP6293852B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP6086869B2 (ja) | 2017-03-08 |
AU2011346823B2 (en) | 2016-08-04 |
MX2013007055A (es) | 2013-11-01 |
CA2822347A1 (en) | 2012-06-28 |
KR20140021532A (ko) | 2014-02-20 |
CA3028414C (en) | 2021-01-26 |
EA022408B1 (ru) | 2015-12-30 |
CN107090476A (zh) | 2017-08-25 |
CN103619336B (zh) | 2017-10-27 |
CA2822347C (en) | 2019-11-05 |
KR101900974B1 (ko) | 2018-09-21 |
AU2011346823A1 (en) | 2013-07-18 |
ES2703433T3 (es) | 2019-03-08 |
EP2654753B1 (en) | 2018-10-31 |
AU2011346823A8 (en) | 2016-09-01 |
JP2017081925A (ja) | 2017-05-18 |
US20140080837A1 (en) | 2014-03-20 |
CN103619336A (zh) | 2014-03-05 |
US9271977B2 (en) | 2016-03-01 |
WO2012085553A1 (en) | 2012-06-28 |
BR112013015501A2 (pt) | 2017-05-16 |
KR101935213B1 (ko) | 2019-01-03 |
JP2014501752A (ja) | 2014-01-23 |
CN107090476B (zh) | 2021-09-24 |
EP2654753A1 (en) | 2013-10-30 |
KR20180027626A (ko) | 2018-03-14 |
JP6293852B2 (ja) | 2018-03-14 |
EP3427737A1 (en) | 2019-01-16 |
CA3028414A1 (en) | 2012-06-28 |
EA201390925A1 (ru) | 2014-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN01156A (es) | ||
PH12015500274A1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
MY173422A (en) | Purine derivatives for the treatment of viral infections | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
MX349827B (es) | Compuestos que contienen nitrogeno y su uso. | |
MX343706B (es) | Derivados heterocíclicos novedosos. | |
PH12015501088A1 (en) | Dimeric compounds | |
MX340533B (es) | Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas. | |
MX2011007930A (es) | Conjugados de insulina cristalina. | |
MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
MY158992A (en) | Forms of rifaximin and uses thereof | |
IN2012DN01269A (es) | ||
GB201209587D0 (en) | Therapeutic compounds | |
MX2015000362A (es) | Benzo(b)-azepin-2-onas antiproliferativas. | |
MX2014006686A (es) | Derivaods novedosos de pirrol. | |
MY170618A (en) | Macrocyclic compounds and methods for their production | |
MX348758B (es) | Derivados de sanglifehrina y metodos para su produccion. | |
PH12015500399A1 (en) | Azaindolines | |
MY159756A (en) | Nitrile derivatives and their pharmaceutical use and compositions | |
PH12015500185B1 (en) | Azaheterocycles as bir2 and/or bir3 inhibitors | |
MX365192B (es) | Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer. | |
MX2013009456A (es) | Compuestos de azufre aromaticos sustituidos y metodos para su uso. | |
TN2013000327A1 (en) | Novel heterocyclic derivatives | |
UA106224C2 (en) | Crystalline insulin-conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |